Summary of ProMIS Neurosciences Conference Call Company Overview - **Company**: ProMIS Neurosciences (Ticker: PMN, Nasdaq) - **Focus**: Treatment of neurodegenerative diseases, primarily in the dementia space, including Alzheimer's, ALS, Parkinson's, and Lewy body dementia [2][3] Key Milestones - **Phase 1b Study**: Completed enrollment of 144 patients for PMN 310, a lead product for Alzheimer's disease, in December 2025 [3] - **Financing**: Successfully raised up to $175 million from a syndicate of investors, ensuring full funding through data readout [3][4] Upcoming Catalysts - **Data Release**: Interim analysis expected mid-2026, with final top-line results by the end of 2026 [4][23] - **Study Design**: Robust 12-month, placebo-controlled, randomized trial aimed at providing definitive answers regarding the efficacy of PMN 310 [4][21] EpiSelect Platform - **Proprietary Technology**: The EpiSelect platform allows for the design of highly selective antibodies targeting toxic oligomers of amyloid beta protein, differentiating ProMIS from competitors [8][10] - **Antibody Development**: PMN 310 is designed to selectively target toxic oligomers while avoiding binding to non-toxic forms, which is a significant advantage over other antibodies [12][16] Safety and Efficacy - **ARIA Management**: The company aims to achieve ARIA (Amyloid-related imaging abnormalities) rates similar to placebo (9%-14%), which would be a significant improvement over existing treatments [24][25] - **Safety Signals**: No treatment-related serious adverse events reported so far, with a lower than expected dropout rate, indicating strong patient enthusiasm [29][30] Biomarker Analysis - **Biomarkers**: A comprehensive panel of biomarkers will be used to assess treatment effects, including p-tau217, neurogranin, and NfL [32][33] - **Predictive Value**: p-tau217 has been identified as a strong predictor of clinical benefit, with expectations for a downward trend in biomarkers indicating drug efficacy [34][41] Future Pipeline and Partnerships - **Expansion Potential**: Successful proof of concept in Alzheimer's could lead to expedited entry into pivotal Phase 3 studies, bypassing Phase 2 trials [44] - **Interest from Pharma**: Ongoing discussions with pharmaceutical companies for potential partnerships, particularly for ALS and other neurodegenerative programs [44][45] Conclusion - **Transformational Year**: 2026 is positioned as a watershed year for ProMIS, with significant data expected that could transform treatment paradigms in Alzheimer's disease and other neurodegenerative conditions [46]